JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the ...

Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against ...

The average one-year price target for Dyadic International (NasdaqCM:DYAI) has been revised to $7.14 / share. This is an ...

These events underscore Dyadic’s commitment to expanding its global footprint and advancing its mission to revolutionize biomanufacturing with its proprietary C1 and Dapibus™ technology platforms.

Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...

Improving patient outcomes, satisfaction and safety while using resources responsibly is foundational to the ever-changing world of kidney health care delivery. Leadership that succeeds clinically and ...

Aiming for the courtroom equivalent of a pin, former collegiate wrestler Mark Emalfarb alleged blue-chip law firms robbed his biotech company of $185 million in vanished market capitalization and $700 ...

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene ...